SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ("Summit", or the "Company") 
 
   SUMMIT THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES 
 
   Oxford, UK, 22 November 2017- Summit Therapeutics plc (NASDAQ: SMMT, 
AIM: SUMM), the drug discovery and development company advancing 
therapies for Duchenne muscular dystrophy ('DMD') and Clostridium 
difficile infection, announces that management will participate in two 
upcoming investor conferences in New York City, US. 
 
 
   -- 29th Annual Piper Jaffray Healthcare Conference - November 28, fireside 
      chat at 1:30pm EST 
 
   -- Oppenheimer Rare Disease Day - December 5 
 
 
   A live audio webcast of the Piper Jaffray fireside chat will be 
available through the Investors section on the Company's website, 
www.summitplc.com. A replay of the webcast will be available from the 
same location soon after the live presentation. For the Oppenheimer Rare 
Disease Day, the Company will participate in one on one meetings. 
 
   About Summit Therapeutics 
 
   Summit is a biopharmaceutical company focused on the discovery, 
development and commercialisation of novel medicines for indications for 
which there are no existing or only inadequate therapies. Summit is 
conducting clinical programs focused on the genetic disease, Duchenne 
muscular dystrophy, and the infectious disease, Clostridium difficile 
infection. Further information is available at www.summitplc.com and 
Summit can be followed on Twitter (@summitplc). 
 
   For more information, please contact: 
 
 
 
 
 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)        Tel:          44 (0)1235 443 951 
Erik Ostrowski / Michelle Avery (US office)                    +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                     Tel:         +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                     Tel:         +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer 
 
Panmure Gordon (Joint Broker)                 Tel:         +44 (0)20 7886 2500 
Freddy Crossley / Duncan Monteith, 
Corporate Finance 
Tom Salvesen, Corporate Broking 
 
MacDougall Biomedical Communications (US)     Tel:             +1 781 235 3060 
Karen Sharma                                             ksharma@macbiocom.com 
 
Consilium Strategic Communications (UK)       Tel:         +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart /                    summit@consilium-comms.com 
Jessica Hodgson / Philippa Gardner 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

November 22, 2017 07:00 ET (12:00 GMT)

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2023 to Apr 2024